We focused our studies on the JIMT-1 breast cancer cell line, which is unique because of having several co-existing trastuzumab resistance mechanisms, including an activating mutation of the PIK3CA gene, low expression of PTEN, high expression of NRG1, and moderate expression of HER2 receptor (despite gene amplification). Here, NRG1 is linked to breast carcinoma.